Use of sevelamer hydrochloride as an oxalate binder - Wikidata - awgldk - TriplyDB

Use of sevelamer hydrochloride as an oxalate binder

Use of sevelamer hydrochloride as an oxalate binder

http://www.wikidata.org/entity/Q37127562

about

The colon: an overlooked site for therapeutics in dialysis patients.Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies.Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations.Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure.Kidney stones: an update on current pharmacological management and future directions.Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.Allopurinol, uric acid, and oxidative stress in cardiorenal disease.Update on oxalate crystal disease.Enteric hyperoxaluria: an important cause of end-stage kidney disease.The intestine and the kidneys: a bad marriage can be hazardous.The management of patients with enteric hyperoxaluria.

P2860

Q34607428-7BF66430-736F-4074-9562-1FAB0D0F6A82 Q36033738-DDFEB5A7-5B6E-4194-A514-00A068677BDE Q36909368-B96412F5-C145-4C5A-873C-E0A4F8DE74A1 Q36947314-7A85EBEB-CD10-459B-8E4C-7E74D0B25A3E Q37169623-5AC09D50-F87E-4EB8-A91C-5346B7E74319 Q37567574-74D772BF-13FB-4EBF-8689-1C362C069F56 Q37872639-08320622-25F9-4180-A3E4-22FD45C57C35 Q38105961-414A86F9-96C9-482E-AE92-BAA25CA2F8F9 Q38363406-79B69D29-FCB8-4C7A-96A6-BDF77C7CC08F Q38393212-F38C4AC1-A264-446D-9D75-97B4BFD1FCC3 Q38662272-A2FEF439-0EC3-427E-94DA-2AE9608A5003

P2860

Use of sevelamer hydrochloride as an oxalate binder

http://www.wikidata.org/entity/Q37127562

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 March 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Use of sevelamer hydrochloride as an oxalate binder

@en

Use of sevelamer hydrochloride as an oxalate binder.

@nl

type

label

Use of sevelamer hydrochloride as an oxalate binder

@en

Use of sevelamer hydrochloride as an oxalate binder.

@nl

prefLabel

Use of sevelamer hydrochloride as an oxalate binder

@en

Use of sevelamer hydrochloride as an oxalate binder.

@nl

P1433

Q37127562-A01576CF-7336-49A9-8B77-07A9B24E42B6

P1476

Q37127562-6AE9F924-2034-4C4D-A136-847474F4CA99

P2093

Q37127562-003708A1-47D5-47FA-99FE-6A884501A169

Q37127562-C45610C6-A8AA-4225-B3A2-43B1C251F6C8

Q37127562-D71CF7DA-32E4-4E1C-82A6-FCFF4024478C

P2860

Q37127562-021F222B-2D3B-4F7A-99FD-488DEA5B3459

Q37127562-21070AFE-A0C7-40E5-9753-3C6D4ACB81CE

Q37127562-2BD64726-F104-48D0-9D62-200FC99B0707

Q37127562-3E8F9C71-DE02-47A0-9F70-CB9B06620283

Q37127562-55BE5423-C764-4950-B6F0-8157D23B6398

Q37127562-6C4DA4CC-FBEE-4FC6-8702-643D5578690F

Q37127562-9A5FD454-D7DD-4F09-986D-7B2DE38F6E2F

Q37127562-A3BDE64E-6023-432F-8834-E05C7BD972A1

Q37127562-CB5670BF-96F6-4CD8-BDFD-3C6645B57BF0

Q37127562-EEA2B48F-039B-4982-B924-A6E5C942D98A

P304

Q37127562-E0635A83-A85B-47DE-A17E-0036236C31BC

P31

Q37127562-4FE58D6B-FA70-480B-A719-2E7637E3FFA6

P356

Q37127562-E14FE1E1-AD7F-4B95-92D0-7EE2277DFA65

P407

Q37127562-D930E8EB-12D1-41B9-B4D3-1BE2E4565092

P433

Q37127562-C0EEF0E6-5324-4D80-BB8B-A01F93397E7B

P478

Q37127562-D33A8505-620C-4124-8693-2434B23D66BD

P577

Q37127562-A6115672-9091-40DB-B26A-C27723F55685

P5875

Q37127562-39A223AA-BA7F-4FF0-8239-9BDD4B21F3AD

P698

Q37127562-B5DD8777-79E2-443B-9C3E-59237257F7D4

P932

Q37127562-70B622C0-0FF4-42D5-BEA4-0757D8DFF23C

P356

J.JURO.2007.11.062

P1433

The Journal of Urology

P1476

Use of sevelamer hydrochloride as an oxalate binder

@en

P2093

Cynthia Regnier

http://www.w3.org/2001/XMLSchema#string

John C Lieske

http://www.w3.org/2001/XMLSchema#string

John J Dillon

http://www.w3.org/2001/XMLSchema#string

P2860

Hyperoxaluria and intestinal disease. The role of steatorrhea and dietary calcium in regulating intestinal oxalate absorption.

Oxalate nephropathy due to gastrointestinal disorders.

Urolithiasis complicating inflammatory bowel disease.

Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass.

Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice.

Hyperoxaluria in malabsorptive states.

The influence of diet on urinary stone disease.

Renal and urologic complications of inflammatory bowel disease.

Evidence for excessive absorption of oxalate by the colon in enteric hyperoxaluria.

Correspondence between stone composition and urine supersaturation in nephrolithiasis.

P304

1407-1410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2007.11.062

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5561757

http://www.w3.org/2001/XMLSchema#string

P698

18289565

http://www.w3.org/2001/XMLSchema#string

P932

2655347

http://www.w3.org/2001/XMLSchema#string